105 related articles for article (PubMed ID: 15183557)
1. Ki-67-directed antisense therapy in an orthotopic renal cell carcinoma model.
Kausch I; Jiang H; Brocks C; Bruderek K; Krüger S; Sczakiel G; Jocham D; Böhle A
Eur Urol; 2004 Jul; 46(1):118-24; discussion 124-5. PubMed ID: 15183557
[TBL] [Abstract][Full Text] [Related]
2. [Ki-67 antisense therapy in murine renal cell carcinoma models].
Kausch I; Jiang H; Brocks C; Albers A; Krüger S; Sczakiel G; Jocham D
Aktuelle Urol; 2005 Apr; 36(2):142-8. PubMed ID: 15902575
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition.
Kausch I; Jiang H; Ewerdwalbesloh N; Doehn C; Krüger S; Sczakiel G; Jocham D
BJU Int; 2005 Feb; 95(3):416-20. PubMed ID: 15679806
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
Verheul HM; Hammers H; van Erp K; Wei Y; Sanni T; Salumbides B; Qian DZ; Yancopoulos GD; Pili R
Clin Cancer Res; 2007 Jul; 13(14):4201-8. PubMed ID: 17634549
[TBL] [Abstract][Full Text] [Related]
5. In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer.
Blietz CE; Thode B; Hauses M; Pries R; Meyer AJ; Doehn C; Jocham D; Kausch I
In Vivo; 2009; 23(1):13-9. PubMed ID: 19368119
[TBL] [Abstract][Full Text] [Related]
6. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
7. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo.
Kausch I; Lingnau A; Endl E; Sellmann K; Deinert I; Ratliff TL; Jocham D; Sczakiel G; Gerdes J; Böhle A
Int J Cancer; 2003 Jul; 105(5):710-6. PubMed ID: 12740923
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer therapy using combined proliferating cell nuclear antigen antisense oligonucleotides and recombinant adenovirus p53.
Zhu Z; Xing S; Lin C; Zhang X; Fu M; Liang X; Zeng F; Lu G; Wu M
Chin Med J (Engl); 2003 Dec; 116(12):1860-3. PubMed ID: 14687474
[TBL] [Abstract][Full Text] [Related]
9. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
[TBL] [Abstract][Full Text] [Related]
11. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.
Soltau J; Zirrgiebel U; Esser N; Schächtele C; Totzke F; Unger C; Merfort I; Drevs J
Anticancer Res; 2008; 28(2A):933-41. PubMed ID: 18507039
[TBL] [Abstract][Full Text] [Related]
12. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
Wu Q; Mahendran R; Esuvaranathan K
Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibiting effects of antisense eukaryotic expression vector of proliferating cell nuclear antigen gene on human bladder cancer cells.
Tong Q; Zeng F; Lin C; Zhao J; Lu G
Chin Med J (Engl); 2003 Aug; 116(8):1203-6. PubMed ID: 12935412
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma.
Ogushi T; Takahashi S; Takeuchi T; Urano T; Horie-Inoue K; Kumagai J; Kitamura T; Ouchi Y; Muramatsu M; Inoue S
Cancer Res; 2005 May; 65(9):3700-6. PubMed ID: 15867365
[TBL] [Abstract][Full Text] [Related]
15. Treatment of transforming growth factor-beta-insensitive mouse Renca tumor by transforming growth factor-beta elimination.
Perry K; Wong L; Liu V; Park I; Zhang Q; Rejen V; Huang X; Smith ND; Jovanovic B; Lonning S; Teicher BA; Lee C
Urology; 2008 Jul; 72(1):225-9. PubMed ID: 18295867
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer.
Tzai TS; Lin CI; Shiau AL; Wu CL
Anticancer Res; 1998; 18(3A):1585-9. PubMed ID: 9673374
[TBL] [Abstract][Full Text] [Related]
18. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model.
Loskog AS; Fransson ME; Totterman TT
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8816-21. PubMed ID: 16361570
[TBL] [Abstract][Full Text] [Related]
19. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for murine renal cell carcinoma using genetically engineered tumor cells to secrete interleukin-12.
Kasaoka Y; Nakamoto T; Wang J; Usui T; Hamada H
Hiroshima J Med Sci; 2000 Mar; 49(1):29-35. PubMed ID: 10824454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
